- Home
- SLM vs ABVX Comparison
SLM vs ABVX Comparison
Compare SLM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- ABVX
- Stock Information
- Founded
- SLM 1972
- ABVX 2013
- Country
- SLM United States
- ABVX France
- Employees
- SLM N/A
- ABVX N/A
- Industry
- SLM Finance: Consumer Services
- ABVX
- Sector
- SLM Finance
- ABVX
- Exchange
- SLM Nasdaq
- ABVX Nasdaq
- Market Cap
- SLM 5.9B
- ABVX 6.7B
- IPO Year
- SLM N/A
- ABVX N/A
- Fundamental
- Price
- SLM $28.28
- ABVX $104.10
- Analyst Decision
- SLM Buy
- ABVX Buy
- Analyst Count
- SLM 12
- ABVX 11
- Target Price
- SLM $33.67
- ABVX $110.36
- AVG Volume (30 Days)
- SLM 3.0M
- ABVX 1.0M
- Earning Date
- SLM 10-23-2025
- ABVX 08-11-2025
- Dividend Yield
- SLM 1.84%
- ABVX N/A
- EPS Growth
- SLM N/A
- ABVX N/A
- EPS
- SLM 2.84
- ABVX N/A
- Revenue
- SLM $1,460,617,000.00
- ABVX $7,073,400.00
- Revenue This Year
- SLM $6.00
- ABVX $6.80
- Revenue Next Year
- SLM $16.24
- ABVX N/A
- P/E Ratio
- SLM $9.91
- ABVX N/A
- Revenue Growth
- SLM N/A
- ABVX N/A
- 52 Week Low
- SLM $23.57
- ABVX $4.77
- 52 Week High
- SLM $34.97
- ABVX $109.71
- Technical
- Relative Strength Index (RSI)
- SLM 58.54
- ABVX 62.91
- Support Level
- SLM $25.95
- ABVX $96.10
- Resistance Level
- SLM $27.12
- ABVX $109.71
- Average True Range (ATR)
- SLM 0.94
- ABVX 5.12
- MACD
- SLM 0.14
- ABVX 0.36
- Stochastic Oscillator
- SLM 57.46
- ABVX 70.47
About SLM SLM Corporation
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.